StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
USPH$62.52-0.01%
Fair $62.52+0.0%

USPH

U.S. Physical Therapy, Inc.

Healthcare / Medical Care FacilitiesNYSE

$62.52

-0.00 (-0.01%)

Fairly Valued+0.0%Fair Value $62.52Fund rank 38/100 · Data gapFallback financials|
SA 37/D
F-Score: 5/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 21% · confianza 25%

FCF escenarios

weak_data · normalized FCF $65.8M · quality 80.0/100

Data gap 38/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 87/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

37/100

D

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 17Warnings: 1unknown: 17
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 3.2%, below the 5% threshold
Thesis & Journal · USPHLocal privado en este navegador · U.S. Physical Therapy, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$952M

P/E

125.0x

↑

EV/EBITDA

11.2x

↓

ROE

3.2%

↑

Gross Margin

19.2%

↓

Debt/Equity

0.66

↑
52-Week Range$63
$58$94

TradingView lightweight chart

USPH price, volumen y niveles de valoración

Último $62.53Periodo +2106.8%
Fair value: $62.52

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2009–2025 · 16 años de histórico normalizado

Revenue CAGR

+8.8%

FCF CAGR

—

FCF margin

7.8%

FCF / Net income

4.05x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $781.0M · net income $15.1M · FCF $61.0M

2009-FY → 2025-FY

Gross margin

19.2%— pts

Operating margin

10.3%-3.7% pts

Net margin

1.9%-3.9% pts

FCF margin

7.8%— pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Income Statement
Revenue$781.0M$781.0M$671.3M$604.8M$553.1M$495.0M$423.0M$482.0M$453.9M$414.1M$356.5M$331.3M$305.1M$264.1M$249.7M$231.5M$211.2M$201.4M
Net Income$15.1M$15.1M$26.5M$14.7M$28.3M$40.8M$35.2M$40.0M$34.9M$22.3M$20.6M$20.6M$19.1M$12.7M$17.9M$21.0M$15.6M$11.8M
EBITDA$109.7M$109.7M$86.9M$74.4M$76.1M$82.2M$62.9M$77.5M$70.1M$64.4M$58.3M$55.2M$52.5M$44.3M$43.7M$36.9M$38.9M$34.1M
EPS1.421.421.841.282.252.412.482.45———1.771.621.051.511.751.321.00
Gross Margin19.2%19.2%18.5%20.1%20.3%23.7%22.3%23.3%22.4%21.9%23.0%23.7%25.0%24.5%25.2%24.1%26.5%—
Operating Margin10.3%10.3%9.8%11.6%11.9%14.3%12.4%14.0%13.3%13.2%13.9%14.3%15.0%14.7%15.4%13.6%15.7%14.0%
Net Margin1.9%1.9%3.9%2.4%5.1%8.2%8.3%8.3%7.7%5.4%5.8%6.2%6.3%4.8%7.2%9.1%7.4%5.8%
Balance Sheet
Debt/Equity0.660.660.600.540.940.400.060.210.180.280.270.280.240.320.150.22——
Current Ratio1.191.19————————————————
Cash Flow
Free Cash Flow$61.0M$61.0M$65.8M$72.7M$50.3M—————————————
Returns
ROE3.2%3.2%5.4%3.1%9.0%13.8%12.7%16.7%16.1%10.9%11.0%12.1%13.1%9.9%15.3%19.6%15.0%—
Valuation
P/E125.05125.0547.9272.4937.49—————————————
EV/EBITDA11.2011.2018.2119.1217.86—————————————
P/B1.991.992.722.763.47—————————————
Growth & Yield
Revenue Growth16.3%16.3%11.0%9.3%—17.0%-12.2%6.2%9.6%16.1%7.6%8.6%15.5%5.8%7.8%9.6%4.9%—
EPS Growth-22.8%-22.8%43.8%-43.1%—-2.8%1.2%————9.3%54.3%-30.5%-13.7%32.6%32.0%—
Dividend Yield2.9%2.9%————————————————

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

57.5%

muy exigente

EPS terminal req.

$5.55

Spread vs growth

-80.3%

5Y implied EPS CAGR

36.4%

muy exigente

EPS terminal req.

$6.71

Spread vs growth

-59.3%

10Y implied EPS CAGR

22.5%

exigente

EPS terminal req.

$10.81

Spread vs growth

-45.3%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -12.8%

Total return

-12.8%

Start / end P/E

40.3x → 44.0x

EPS bridge

1.84 → 1.42

Residual

-2.1%

EPS growth-22.8%
Multiple rerating+9.2%
Dividend+2.9%
Residual / FX / buybacks / cross-term-2.1%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.